Evolus to Participate in the Needham 25th Annual Virtual Healthcare Conference
Evolus, Inc. announced that its management team will participate in a fireside chat and investor meetings at the Needham 25th Annual Virtual Healthcare Conference on Tuesday, April 14, 2026, at 3:45 PM ET. The fireside chat will be accessible via their Investor Relations page, with a replay available for 90 days. Evolus is a performance beauty company focused on aesthetic injectables like Jeuveau and Evolysse.
Evolus to Participate in the Needham 25th Annual Virtual Healthcare Conference
Evolus, Inc. announced its management team will participate in a fireside chat and investor meetings at the Needham 25th Annual Virtual Healthcare Conference on April 14, 2026, at 3:45 PM ET. The performance beauty company focuses on building an aesthetic portfolio of consumer brands and redefining the aesthetic injectable market. A webcast of the fireside chat will be available on the Investor Relations page of the Evolus website.
Evolus, Inc. (NASDAQ:EOLS) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Evolus, Inc. (NASDAQ:EOLS) has received a "Moderate Buy" consensus rating from analysts, with an average 12-month price target of $16.00. Despite this, insiders have recently sold a significant number of shares, and the company's stock is trading near its 1-year low after missing quarterly EPS estimates. Institutional investors, however, have shown mixed activity, with some increasing and some decreasing their stakes.
Vanguard disaggregates holdings for Evolus (NASDAQ: EOLS) after internal realignment
The Vanguard Group has filed an amended Schedule 13G for Evolus (EOLS), reporting 0% beneficial ownership of the common stock. This change is due to an internal realignment within Vanguard, leading to disaggregated reporting by its subsidiaries in accordance with SEC Release No. 34-39538, effective January 12, 2026. The filing explicitly states that this is a procedural change in reporting structure and does not indicate a sale of shares by Vanguard.
Avelar Rui sells Evolus (EOLS) shares worth $14815
Rui Avelar, an officer at Evolus, Inc. (NASDAQ:EOLS), sold 3,119 shares of common stock worth $14,815 on March 20, 2026, at a weighted average price of $4.75. This transaction was part of a Rule 10b5-1 trading plan to cover tax withholding obligations related to restricted stock unit awards. The sale occurred while the stock is trading near its 52-week low, and comes amidst recent news of Evolus missing Q4 2025 revenue expectations and a board reclassification.
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Evolus, Inc. (NASDAQ: EOLS) granted 85,516 restricted stock units (RSUs) and 8,635 stock options to 10 newly hired non-executive employees in March 2026. These inducement awards were approved by the compensation committee under the company's 2023 Inducement Incentive Plan and comply with Nasdaq Listing Rule 5635(c)(4). The awards vest 25% annually and are subject to continuous employment.
Evolus (NASDAQ: EOLS) insider sells 13,669 shares to cover taxes
Evolus (NASDAQ: EOLS) director and officer David Moatazedi sold 13,669 shares of common stock at a weighted average price of $4.7501 per share under a Rule 10b5-1 trading plan. This sale was conducted to cover tax withholding obligations associated with restricted stock unit awards. Following the transaction, Moatazedi retains a direct holding of 604,700 Evolus shares, indicating a tax-driven adjustment rather than a change in his equity position.
Avelar Rui sells Evolus (EOLS) shares worth $14815
Rui Avelar, an officer at Evolus, Inc. (NASDAQ:EOLS), sold 3,119 shares of common stock for $14,815 to cover tax withholding obligations. This transaction occurred as the stock trades near its 52-week low. The company recently reported a slight miss in Q4 2025 revenue expectations and a change in its board of directors.
Evolus CEO Moatazedi sells $64929 in shares
Evolus, Inc. CEO David Moatazedi sold 13,669 shares of common stock for approximately $64,929 on March 20, 2026, to cover tax withholding obligations. The company's stock has declined 30% year-to-date and is trading near its 52-week low. Despite the stock performance, two analysts have recently revised earnings upward, though the company missed fourth-quarter 2025 revenue expectations.
Evolus (EOLS) officer tax-driven sale of 3,119 shares under 10b5-1 plan
Evolus, Inc. officer Rui Avelar sold 3,119 shares of common stock at a weighted average price of $4.75 per share. This sale was conducted under a pre-arranged Rule 10b5-1 trading plan to cover tax withholding obligations from restricted stock unit settlements. Following the transaction, Avelar directly holds 427,423 Evolus shares, indicating it was a small, tax-related sale.
Avelar Rui, chief medical officer at Evolus, sells $146k in EOLS stock
Avelar Rui, Chief Medical Officer at Evolus, Inc. (NASDAQ:EOLS), sold nearly $146,629 worth of company stock after the vesting of restricted stock units. Following the transaction, Rui directly holds 430,542 shares of Evolus. This sale occurred shortly after Evolus reported a slight miss on Q4 2025 revenue expectations and announced changes to its board of directors.
David Moatazedi Sells 116,720 Shares of Evolus (NASDAQ:EOLS) Stock
David Moatazedi, an insider at Evolus (NASDAQ:EOLS), sold 116,720 shares of the company's stock on March 17th for a total of $570,760.80, reducing his ownership by 15.88%. This sale comes as the stock trades near its 50-day moving average, and after the company reported an EPS miss for the quarter. Despite the insider sale and EPS miss, analysts maintain a "Moderate Buy" consensus rating with an average price target of $16.00.
Insider Selling: Evolus (NASDAQ:EOLS) Insider Sells 29,996 Shares of Stock
Evolus (NASDAQ:EOLS) insider Rui Avelar sold 29,996 shares of the company's stock for approximately $146,680.44 on March 17th, reducing his stake by 6.51%. The sale followed the company reporting $0.00 EPS, missing estimates, and shares have since traded down. Analysts have a "Moderate Buy" consensus rating with an average price target of $16.00, despite mixed views.
Avelar Rui, chief medical officer at Evolus, sells $146k in EOLS stock
Avelar Rui, Chief Medical Officer at Evolus, Inc. (NASDAQ:EOLS), sold nearly $147,000 worth of company stock to cover tax withholding obligations following the vesting of performance restricted stock units. Despite this sale, Avelar Rui still directly owns over 430,000 shares. The company recently reported a slight miss on Q4 2025 revenue expectations and made changes to its board of directors to maintain governance balance.
[Form 4] Evolus, Inc. Insider Trading Activity
Evolus, Inc. director and officer David Moatazedi reported insider trading activity, including the vesting of 67,489 performance restricted stock units and the subsequent sale of 116,720 shares of common stock. These sales, executed under a Rule 10b5-1 trading plan, were primarily to cover tax withholding obligations related to the equity awards. Following these transactions, Moatazedi's direct holdings in Evolus common stock stand at 618,369 shares.
Evolus (EOLS) executive sells 29,996 shares after PSU vesting
Evolus executive Rui Avelar sold 29,996 shares of common stock at a weighted average price of $4.8883 per share to cover tax obligations following the vesting of performance restricted stock units (PSUs). On March 16, 2026, 8,804 PSUs vested, with an additional 8,802 PSUs scheduled to vest in February 2027. After these transactions, Avelar directly holds 430,542 shares of Evolus common stock.
Evolus CEO Moatazedi sells $570k in shares
Evolus CEO David Moatazedi sold 116,720 shares of company stock worth approximately $570,562 on March 17, 2026, primarily to cover tax obligations related to vesting stock units. This transaction occurred under a pre-arranged trading plan, and despite the sale, Moatazedi maintains a direct ownership of over 618,000 shares. The company's shares are currently trading near a 52-week low, and recent earnings reports indicate a slight revenue miss, though some analysts have revised earnings estimates upward.
(EOLS) as a Liquidity Pulse for Institutional Tactics
Evolus Inc. (NASDAQ: EOLS) is highlighted with a near-term weak sentiment, a mid-channel oscillation pattern, and an exceptional risk-reward setup targeting a 24.2% gain. The article provides three institutional trading strategies (Position, Momentum Breakout, and Risk Hedging) with specific entry, target, and stop-loss zones. It also includes a multi-timeframe signal analysis, showing varying signal strengths and support/resistance levels for different time horizons.
Evolus, Inc. Files Form 8-K Announcing Executive Changes and Company Information (March 13, 2026)
Evolus, Inc. filed a Form 8-K to announce executive changes reclassifying an existing director, Mr. Malik, to Class II to rebalance the board structure after a resignation. The board remains at six directors, evenly distributed among three classes, with no new compensation or related-party transactions for Mr. Malik. This administrative update ensures proper corporate governance without impacting company leadership or shareholder compensation.
Evolus (EOLS) reclassifies chairman Vikram Malik to restore board balance
Evolus, Inc. announced the reclassification of its Chairman, Vikram Malik, from Class III to Class II director to restore balance to its classified board. This technical change was necessitated by the departure of a former director, Simone Blank, and ensures an even distribution of two directors across each of the three board classes. Malik's continuous service on the board, his role as Chairman, and his existing equity awards remain unaffected by this reclassification.
Evolus reclassifies Vikram Malik to Class II director to balance board
Evolus, Inc. announced the reclassification of Vikram Malik from a Class III to a Class II director to rebalance its board after a previous departure. Mr. Malik will continue as Chairman and a member of the Compensation Committee, serving until the 2026 annual meeting. The company's board now consists of six directors, with two in each class, and InvestingPro analysis suggests the stock is currently undervalued.
Vikram Malik reclassified to Class II director at Evolus
Evolus has reclassified Vikram Malik from a Class III to a Class II director, effective March 13, 2026. This change aims to restore balance among director classes after a previous departure, with Malik retaining his roles as Chairman and Compensation Committee member. His service on the board remains continuous, and his existing equity awards will continue to vest as originally planned.
Evolus reclassifies Vikram Malik to Class II director to balance board
Evolus (NASDAQ:EOLS) has reclassified Vikram Malik from a Class III to a Class II director to balance its board structure following a previous departure. Malik will continue as Chairman of the Board and a member of the Compensation Committee, with his existing equity awards remaining unchanged. This move ensures the board maintains two directors in each of its three classes.
Evolus, Inc. (NASDAQ:EOLS) Q4 2025 earnings call transcript
This document is a transcript of the Q4 2025 earnings call for Evolus, Inc. (NASDAQ:EOLS). It contains details of the company's financial performance and discussions held during the call.
Evolus (NASDAQ: EOLS) outlines 2025 losses, Jeuveau and Evolysse growth plans
Evolus Inc. (NASDAQ: EOLS) reported a net loss of $51.6 million in 2025, bringing its accumulated deficit to $661.0 million, despite an 11.6% increase in net revenues to $297.2 million, driven by the launch of Evolysse in the US and growth in Jeuveau sales. The company's strategy focuses on the cash-pay medical aesthetics market with its neurotoxin Jeuveau and hyaluronic acid gels Evolysse, planning further product launches in Europe and regulatory approvals in the US. Evolus highlights ongoing reliance on manufacturing and licensing partners, competitive pressures, and dependence on consumer discretionary spending as key challenges.
(EOLS) Risk Channels and Responsive Allocation
This article provides an AI-generated analysis of Evolus Inc. (NASDAQ: EOLS), highlighting near to mid-term strong sentiment but a weak long-term outlook. It details specific trading strategies for different risk profiles, including long, breakout, and short setups, along with key support and resistance levels. The analysis emphasizes an exceptional risk-reward short setup targeting a 20.1% downside.
Evolus (NASDAQ:EOLS) Rating Increased to Buy at Wall Street Zen
Wall Street Zen has upgraded Evolus (NASDAQ:EOLS) from a "hold" to a "buy" rating, contributing to a consensus "Moderate Buy" rating with an average analyst target price of $16.00. Despite missing Q4 EPS estimates, Evolus reported revenues slightly above expectations, though its shares currently trade well below their 52-week high with a negative P/E ratio. The company exhibits high institutional ownership at 90.69%, with insiders holding 5.90%, and notable institutional movements including new stakes and increased positions from various investors.
Evolus, Inc. (NASDAQ:EOLS) Q4 2025 Earnings Call Transcript
Evolus, Inc. reported its Q4 and full-year 2025 financial results, highlighting 12% full-year revenue growth despite a declining U.S. aesthetics market. The company emphasized its "beauty-first" strategy, product differentiation with Jeuveau and Evolysse, and expansion into international markets, aiming for significant adjusted EBITDA margins by 2028. Management discussed the success of portfolio growth rebates and patient loyalty programs, while also preparing for new product launches and competitive market dynamics in 2026.
BTIG Reiterates Buy Rating for Evolus (EOLS) with $13 Target | E
BTIG analyst Sam Eiber has reiterated a "Buy" rating for Evolus (EOLS) with a $13.00 price target, signaling continued confidence in the company's market performance. This comes amidst varying price targets from other analysts, though a consensus "Outperform" status and an average target price of $14.67 suggests significant upside potential from its current price. Evolus, a performance beauty company, focuses on the self-pay aesthetic market with its primary product Jeuveau, a botulinum toxin for frown lines.
Evolus, Inc. (EOLS) Matches Q4 Earnings Estimates
Evolus, Inc. (EOLS) reported Q4 earnings of $0.06 per share, matching the Zacks Consensus Estimate, and revenues of $90.3 million, surpassing estimates by 0.98%. Despite beating revenue expectations in two of the last four quarters, the stock has seen a significant decline this year. The current earnings outlook for Evolus is unfavorable, holding a Zacks Rank #4 (Sell), suggesting potential underperformance.
Evolus (NASDAQ:EOLS) Issues Quarterly Earnings Results
Evolus (NASDAQ:EOLS) reported Q4 EPS of $0.00, missing the consensus of $0.09, but revenue surprisingly beat estimates at $90.3 million, leading to a 29.8% stock jump. Management also raised its 2026 revenue guidance and expects full-year profitability, despite ongoing market headwinds like tariffs and new competitor launches. Insider selling activity was noted, while institutional investors largely increased their stakes in the company, and analysts generally maintain a "Moderate Buy" rating with a consensus target price of $17.50.
Earnings call transcript: Evolus misses Q4 2025 revenue forecast, stock dips
Evolus reported a Q4 2025 revenue of $90.3 million, missing the forecast of $90.75 million, which led to a 3.96% dip in its stock price in aftermarket trading. Despite the revenue miss, the company highlighted strong international growth and strategic organizational changes made in 2025 aimed at sustainable profitability, projecting a return to annual profitability in 2026. Evolus also discussed its differentiated product portfolio, including Jeuveau and the new Evolysse, and provided 2026 guidance forecasting total net revenues between $327 million and $337 million.
Evolus Shares Up 17% on Q4, Full Year Earnings
Evolus Inc. saw its shares jump 17% after reporting strong fourth quarter and full-year earnings, achieving nearly $300 million in total net revenue for 2025. CEO David Moatazedi expects continued double-digit growth in 2026, with revenue guidance set between $327 million and $337 million, supported by upcoming product approvals and launches.
Evolus, Inc. 2025 Q4 - Results - Earnings Call Presentation
Evolus, Inc. (EOLS) published its Q4 2025 earnings call presentation, reporting an EPS of $0.01, missing estimates by $0.02, and revenue of $90.30M, which beat by $718.57K, representing a 14.38% increase year-over-year. This presentation accompanies their earnings call from March 3, 2026, providing key financial insights for investors.
Evolus Inc. (EOLS) Stock Rises on Q4 2025 Earnings
Evolus Inc. (EOLS) reported its fourth-quarter 2025 earnings, with revenue increasing 14.4% year-over-year to $90.3 million, though slightly below analyst estimates. The stock rose 9.96% after market close despite significant decreases in net income and diluted EPS compared to the previous year. The report also detailed recent insider trading activity, hedge fund movements, and current analyst ratings and price targets.
Evolus (NASDAQ: EOLS) wins $30M credit line and 12% 2025 sales rise
Evolus, Inc. (NASDAQ: EOLS) secured a new senior secured, asset-based revolving credit facility of up to $30 million, maturing on March 3, 2029. The company reported a 12% increase in total net revenue for 2025, reaching $297.2 million, and projects 2026 revenue to grow by 10-13%. Despite continued net losses in 2025, Evolus achieved GAAP operating income in Q4 2025 and aims for positive Adjusted EBITDA margins by 2026 and 13-15% by 2028.
Evolus Reports Fourth Quarter and Full-Year 2025 Financial Results; Delivers Sixth Consecutive Year of Double-Digit Growth and Expects Sustainable Profitability1 Beginning in 2026
Evolus, Inc. announced its financial results for the fourth quarter and full-year ended December 31, 2025, reporting $90.3 million in net revenue for Q4 and $297.2 million for the full year, marking its sixth consecutive year of double-digit growth. The company also achieved GAAP operating income of $4.2 million for Q4 2025, exceeding prior guidance. Evolus provided 2026 net revenue guidance of $327 million to $337 million, expecting 10% to 13% growth and projecting low- to mid-single-digit Adjusted EBITDA margins by 2026, with long-term targets of $450-$500 million in revenue and 13%-15% Adjusted EBITDA margins by 2028.
Evolus, Inc. (NASDAQ:EOLS) Given Average Recommendation of "Moderate Buy" by Brokerages
Evolus, Inc. (NASDAQ:EOLS) has received an average recommendation of "Moderate Buy" from seven brokerages, with an average one-year target price of $17.50, significantly higher than its current share price of $4.25. The company's stock is trading near its 52-week low despite strong institutional ownership of 90.69%, though an insider recently sold a notable number of shares. Analysts' price targets range from $13.00 to $20.00, suggesting considerable upside potential according to these financial experts.
Beauty firm Evolus to field investor questions at Miami healthcare event
Evolus, Inc. announced that its management team will attend the Leerink Partners Global Healthcare Conference in Miami, FL. They will participate in a fireside chat and investor meetings on Wednesday, March 11, 2026, at 11:20 AM ET. The fireside chat will be accessible via webcast on the Evolus Investor Relations page, with a replay available for 90 days.
Evolus to Participate in The Leerink Partners Global Healthcare Conference
Evolus, Inc. announced that its management team will participate in a fireside chat and investor meetings at the upcoming Leerink Partners Global Healthcare Conference in Miami, FL. The fireside chat is scheduled for Wednesday, March 11, 2026, at 11:20 AM ET and will be accessible via webcast on the Evolus Investor Relations page, with a replay available for 90 days. Evolus aims to redefine the aesthetic injectable market with products like Jeuveau® and Evolysse™.
Evolus to Participate in The Leerink Partners Global Healthcare Conference
Evolus, Inc. announced that its management team will participate in the Leerink Partners Global Healthcare Conference in Miami, FL. The team will engage in a fireside chat and investor meetings starting March 11, 2026, at 11:20 AM ET. A webcast of the fireside chat will be available on the Evolus Investor Relations page.
Evolus to Participate in The Leerink Partners Global Healthcare Conference
Evolus, Inc. announced that its management team will participate in a fireside chat and investor meetings at the Leerink Partners Global Healthcare Conference on Wednesday, March 11, 2026, at 11:20 AM ET. The webcast of the fireside chat will be accessible on the Investor Relations page of the Evolus website, with a replay available for 90 days. Evolus is a global performance beauty company focusing on aesthetic injectables like Jeuveau and Evolysse.
Evolus (EOLS) Expected to Announce Earnings on Tuesday
Evolus (EOLS) is scheduled to release its Q4 2025 earnings after market close on Tuesday, March 3rd, with analysts anticipating earnings per share of $0.09 and revenue of $89.581 million. The stock traded down about 0.9%, opening at $4.33, and has a "Moderate Buy" consensus rating from analysts with an average target price of $17.50. Recent insider activity showed a sale of 10,539 shares by David Moatazedi, while institutional investors hold a significant portion of the company's stock.
Evolus, Inc. (EOLS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Evolus, Inc. (EOLS) is projected to report a significant year-over-year increase in earnings and higher revenues for the quarter ended December 2025, with results expected on March 3rd. Analysts anticipate quarterly earnings of $0.06 per share, a 500% rise, and revenues of $89.42 million, up 13.3%. Despite a positive Earnings ESP of +8.33%, the stock's Zacks Rank #4 suggests it's difficult to definitively predict an earnings beat.
Evolus, Inc. (EOLS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Evolus, Inc. (EOLS) is expected to report a significant year-over-year increase in earnings and higher revenues for the quarter ended December 2025, with results anticipated on March 3. The company has a positive Earnings ESP of +8.33%, indicating analysts are bullish, but a Zacks Rank of #4 makes a definitive earnings beat difficult to predict. Investors are advised to consider other factors alongside the Earnings ESP and Zacks Rank.
Evolus (NASDAQ: EOLS) grants RSUs, PSUs and options to executive David Moatazedi
Evolus (NASDAQ: EOLS) has granted various equity awards, including performance-based restricted stock units (PSUs), time-based restricted stock units (RSUs), and stock options, to its executive David Moatazedi, as detailed in an SEC Form 4 filing on February 17, 2026. The PSUs are tied to financial metrics and relative total shareholder return over a three-year period, while the RSUs and stock options vest in four equal annual installments starting February 17, 2026, contingent on continued service. These grants are part of Moatazedi's compensation package and were awarded at a price of $0.00.
Major holder Timothy P. Lynch reports 9.9% stake in Evolus (EOLS)
Timothy P. Lynch has reported a 9.9% beneficial ownership stake in Evolus, Inc. (EOLS) through an amended SCHEDULE 13G/A filing. This stake comprises 6,425,726 shares of common stock, with both sole and shared voting/dispositive power over portions of the shares. Lynch explicitly states that the securities were not acquired for the purpose of changing or influencing control of Evolus.
Director at Evolus (EOLS) receives 45,559 RSUs in equity award
Evolus, Inc. director Vikram Malik was granted an equity award of 45,559 restricted stock units (RSUs). These RSUs, which represent the right to receive one share of common stock each, will vest fully on February 17, 2027, provided Malik continues in service. Following this grant, Malik's beneficial ownership in Evolus common stock totals 321,109 shares.
Botulinum Toxins Market Size & Growth Forecast to 2030
The global botulinum toxins market is projected to reach USD 15.72 billion by 2030, growing at a CAGR of 12.0% from USD 8.92 billion in 2025, driven by increasing aesthetic consciousness and expanding therapeutic applications. Key players include AbbVie, Ipsen, and Galderma, with significant market share in North America, while the Asia Pacific region is expected to show the highest growth. The market is influenced by a shift towards minimally invasive procedures, biosimilar competition, and product innovation.
Evolus to Report Fourth Quarter and Full-Year 2025 Financial Results on March 3, 2026
Evolus, Inc. announced its plan to report fourth quarter and full-year 2025 financial results on Tuesday, March 3, 2026, after the U.S. financial markets close. The company will host a conference call and live webcast at 4:30 p.m. ET on the same day to discuss these results, followed by a question-and-answer session. Details for participating in the call and accessing replays are provided.
